THRB and metabolic dysfunction-associated steatotic liver disease: Since hypothyroidism and NAFLD seem to share common pathophysiological mechanisms, THR-b selective agonists are developed to provide specific effects in the liver, aiming to reduce fat accumulation while avoiding the side effects of systemic hyperthyroidism and, therefore, represent potential therapeutic molecules targeting NAFLD caused by hypothyroidism-associated dyslipidemia.